Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Eterna Therapeutics Inc. Market Cap
The Eterna Therapeutics Inc. (ERNA) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ERNA. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for ERNA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedERNA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Eterna Therapeutics Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ERNA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ERNA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Morgan Stanley | Equal-Weight | Maintains | Dec 14, 2022 | |
B of A Securities | Buy | Upgrade | Dec 12, 2022 | |
Needham | Buy | Maintains | Nov 14, 2022 | |
Needham | Buy | Maintains | Aug 10, 2022 | |
Morgan Stanley | Equal-Weight | Maintains | Jul 15, 2022 | |
JP Morgan | Overweight | Upgrade | May 12, 2022 | |
Needham | Buy | Maintains | May 11, 2022 | |
Needham | Buy | Maintains | Mar 2, 2022 | |
Needham | Buy | Maintains | Nov 11, 2021 | |
Needham | Buy | Maintains | Oct 1, 2021 | |
Morgan Stanley | Equal-Weight | Maintains | Jun 16, 2021 | |
Needham | Buy | Maintains | May 13, 2021 | |
JP Morgan | Neutral | Initiates | Apr 21, 2021 | |
Needham | Buy | Maintains | Apr 19, 2021 | |
Morgan Stanley | Equal-Weight | Initiates | Mar 26, 2021 | |
Needham | Buy | Maintains | Mar 25, 2021 |
When did it IPO
N/A
Staff Count
8
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Sanjeev Luther
Market Cap
$9.7M
In 2023, ERNA generated $68,000 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ERNA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 06 Sep 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications
Tue, 05 Sep 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA ) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors.
Tue, 11 Jul 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Brant Binder and Richard Wagner, Ph.D. to its Board of Directors. Concurrently, Charles Cherington and Nicholas Singer have stepped down from the Board.
Wed, 24 May 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Megan Yung as Chief Strategy Officer and General Counsel. Ms. Yung will work with Eterna's senior leadership and the Board of Directors to develop and advance the Company's corporate strategy. Ms. Yung will also oversee the company's legal activities, including licensing and intellectual property matters.
Wed, 17 May 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease
Thu, 04 May 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene insertion
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
